Morgan Stanley
BIVV

Morgan Stanley’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Morgan Stanley’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-306,976
Closed -$16.6M – 6842
2017
Q4 		$16.6M Sell
306,976
-188,200
-38% -$10.3M ﹤0.01% 1856
2017
Q3 		$28.3M Buy
495,176
+178,422
+56% +$10.5M 0.01% 1302
2017
Q2 		$19.1M Sell
316,754
-419,356
-57% -$23.9M 0.01% 1580
2017
Q1 		$40.1M Buy
+736,110
New +$36.3M 0.01% 1044

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Morgan Stanley's BIVV Position: Q1 2018 in Review

Morgan Stanley sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 306,976 shares — an estimated $16.6M sold.

Morgan Stanley first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $40.1M in Q1 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Morgan Stanley reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Morgan Stanley sold 306,976 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $16.6M.
  • Morgan Stanley first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Morgan Stanley's Bioverativ Inc. Common Stock position peaked at $40.1M in Q1 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Morgan Stanley's 13F filing for Q1 2018, filed 14 May 2018.